PML-controlled responses in severe congenital neutropenia withELANE-misfolding mutations
PML-контролируемые ответы при тяжелой врожденной нейтропении с мутациями ELANE, приводящими к неправильной свертке
2021-02-03
SCID: 54.1/sww9ax52
Discuss with AI
CSF3 (granulocyte colony-stimulating factor) responseELANE misfolding mutationspromyelocyte leukemia protein (PML)promyelocyte leukemia protein (PML) nuclear bodiesreactive oxygen species (ROS)severe congenital neutropenia (SCN)
Figures from the paper
Abstract (AI)
Mutations in ELANE cause severe congenital neutropenia (SCN), but how they affect neutrophil production and contribute to leukemia predisposition is unknown. Neutropenia is alleviated by CSF3 (granulocyte colony-stimulating factor) therapy in most cases, but dose requirements vary between patients. Here, we show that CD34+CD45+ hematopoietic progenitor cells (HPCs) derived from induced pluripotent stem cell lines from patients with SCN that have mutations in ELANE (n = 2) or HAX1 (n = 1) display elevated levels of reactive oxygen species (ROS) relative to normal iPSC-derived HPCs. In patients with ELANE mutations causing misfolding of the neutrophil elastase (NE) protein, HPCs contained elevated numbers of promyelocyte leukemia protein nuclear bodies, a hallmark of acute oxidative stress. This was confirmed in primary bone marrow cells from 3 additional patients with ELANE-mutant SCN. Apart from responding to elevated ROS levels, PML controlled the metabolic state of these ELANE-mutant HPCs as well as the expression of ELANE, suggestive of a feed-forward mechanism of disease development. Both PML deletion and correction of the ELANE mutation restored CSF3 responses of these ELANE-mutant HPCs. These findings suggest that PML plays a crucial role in the disease course of ELANE-SCN characterized by NE misfolding, with potential implications for CSF3 therapy.
Key Findings
1
Deletion of PML or correction of the ELANE mutation restores CSF3 (G-CSF) responsiveness in ELANE-mutant HPCs, implicating PML as crucial for altered CSF3 therapy responses.
2
Deletion of PML or correction of the ELANE mutation restores CSF3 (G-CSF) responsiveness in ELANE-mutant HPCs, linking PML to variable CSF3 therapy responses.
3
ELANE mutations that cause neutrophil elastase (NE) misfolding lead to increased numbers of promyelocyte leukemia protein (PML) nuclear bodies in HPCs, indicating acute oxidative stress.
4
Elevated PML levels were confirmed in primary bone marrow cells from three additional patients with ELANE-mutant SCN.
5
HPCs derived from iPSCs of SCN patients with ELANE or HAX1 mutations show elevated reactive oxygen species (ROS) compared to normal iPSC-derived HPCs.
6
HPCs with ELANE mutations that cause neutrophil elastase (NE) misfolding have increased numbers of promyelocyte leukemia protein (PML) nuclear bodies, a marker of acute oxidative stress.
7
PML regulates both the metabolic state of ELANE-mutant HPCs and the expression of ELANE, implying a feed-forward disease mechanism driven by PML in NE misfolding cases.
8
PML regulates the metabolic state of ELANE-mutant HPCs and controls ELANE expression, indicating a potential feed-forward mechanism in disease progression.
9
Primary bone marrow cells from three additional ELANE-mutant SCN patients also exhibit elevated PML nuclear bodies, confirming findings from iPSC-derived HPCs.
10
iPSC-derived CD34+CD45+ hematopoietic progenitor cells (HPCs) from SCN patients with ELANE or HAX1 mutations show elevated reactive oxygen species (ROS) versus normal iPSC-derived HPCs.
Research Object
CD34+CD45+ hematopoietic progenitor cells (HPCs) derived from iPSC lines of patients with severe congenital neutropenia caused by ELANE misfolding mutations
Research Subject
Role of PML in controlling oxidative-stress-associated nuclear bodies, metabolic state, ELANE expression, and CSF3 responsiveness in ELANE-misfolding SCN HPCs
Publication Details
Publication Date
2021-02-03
Journal
Publisher
ISSN
Cited by
18
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest